Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

SLNOยทNASDAQ

$53.01

+0.038%
HealthcareBiotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$2.76B
EPS0.4100
P/E Ratio117.86
Earnings Date08/05/2026

No Dividend Yield Data

SLNO has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

SLNO has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

SLNO has not reported any net dividends paid values in the available annual periods.

Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Dividend History

SLNO ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

SLNO Dividend Payment History

SLNO ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
slno

Soleno Therapeutics, Inc. Payout Ratio Analysis

SLNO ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
20.89M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Excellent FCF coverage. Dividend is well-supported by actual cash generation with ample room for increases and business reinvestment.

Sustainability
Fair

Dividend sustainability questionable. Monitor closely for signs of stress. Consider whether yield justifies the risk.